

6. (Amended) A method of treating a mammal with vaginal dryness by administering an effective vaginal dryness treatment amount of a compound of Formulas I, [II], III, or IV as described in [claims 1-5] Claim 1 or 4.

7. (Amended) A pharmaceutical composition comprising a compound of Formulas I, [II], III, or IV as described in [claims 1-5] Claim 1 or 4 together with a pharmaceutically acceptable carrier therefor in the form of a liquid or gel suspension.

A2
8. (Amended) The method of claim 6 wherein the amount of compound of Formulas I, [II], III or IV administered to the mammal is sufficient to achieve a concentration on the cervical and/or vaginal mucosa of from about 10^{-7} moles/liter to about 10^{-1} moles/liter.

9. (Amended) The method of claim 6 wherein the amount of compound of Formulas I, [II], III, or IV administered to the mammal is sufficient to achieve a daily dose of between 1 to 1000 milligrams.

10. (Amended) A method of treating a mammal with vulvar pain by administering an effective vulvar pain treatment amount of a compound of Formulas I, [II], III, or IV as described in [claims 1-5] Claim 1 or 5.

REMARKS


The Amendment

The above amendments cancel Formula II from the claims.

No new matter is added in any of the amendments. The Examiner is respectfully requested to enter all the amendments.

Respectfully submitted,

Date: October 9, 2001


Albert P. Halluin (Reg. No. 25,227)
Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
(650) 463-8109



Attorney Docket No.: 03678.0028.US04


Application No.: 09/531,851

RECEIVED
OCT 16 2001
TECH CENTER 116012900

CLEAN VERSION OF ALL PENDING CLAIMS

1. A method of stimulating cervical and vaginal secretions in a mammal in need thereof by administering an effective secretion stimulating amount of a compound of Formula I, III, or IV:

Formula I




wherein:

X₁, X₂ and X₃ are each independently either O⁻ or S⁻;

R₁ is O, imido, methylene or dihalomethylene;

R₂ is H or Br; preferably, R₂ is H; or

Formula III




wherein:

R_1 , X_1 , X_2 and X_3 are defined as in Formula I;

R_5 and R_6 are H while R_7 is nothing and there is a double bond between N-3 and C-4 (cytosine), or

R_5 , R_6 and R_7 taken together are $-\text{CH}=\text{CH}-$, forming a ring from N-3 to N-4 with a double bond between N-4 and C-4 (3, N^4 -ethenocytosine) optionally substituted at the 4- or 5-position of the etheno ring; or

Formula IV



wherein:

R_1 , X_1 , X_2 , and X_3 are defined as in Formula I;

R_3 and R_4 are H while R_2 is nothing and there is a double bond between N-1 and C-6 (adenine), or

R_3 and R_4 are H while R_2 is O and there is a double bond between N-1 and C-6 (adenine 1-oxide), or

R₃, R₄, and R₂ taken together are -CH=CH-, forming a ring from N-6 to N-1 with a double bond between N-6 and C-6 (1,N6-ethenoadenine);
or pharmaceutically acceptable esters or salts thereof.

4. The method of claim 1 wherein R₂ of Formula I is H.
6. A method of treating a mammal with vaginal dryness by administering an effective vaginal dryness treatment amount of a compound of Formulas I, III, or IV as described in Claim 1 or 4.
7. A pharmaceutical composition comprising a compound of Formulas I, III, or IV as described in Claim 1 or 4 together with a pharmaceutically acceptable carrier therefor in the form of a liquid or gel suspension.
8. The method of claim 6 wherein the amount of compound of Formulas I, III or IV administered to the mammal is sufficient to achieve a concentration on the cervical and/or vaginal mucosa of from about 10⁻⁷ moles/liter to about 10⁻¹ moles/liter.
9. The method of claim 6 wherein the amount of compound of Formulas I, III, or IV administered to the mammal is sufficient to achieve a daily dose of between 1 to 1000 milligrams.
10. A method of treating a mammal with vulvar pain by administering an effective vulvar pain treatment amount of a compound of Formulas I, III, or IV as described in Claim 1 or 5.